{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(11)"],"submitter":["Cosman F"],"funding":["UCB Pharma","Amgen"],"pubmed_abstract":["Increases in bone mineral density (BMD) with osteoporosis treatment are associated with reduced fracture risk. Increasing BMD is therefore a goal of osteoporosis therapy. Here, we compare the probability of achieving a <i>T</i>-score of > -2.5 over 3 years at the total hip (TH) or lumbar spine (LS) in women with osteoporosis, ≥55 years of age, after the following treatment sequences: 1 year romosozumab followed by 2 years denosumab (FRAME and FRAME extension trials), 1 year romosozumab followed by 2 years alendronate, or alendronate-only for 3 years (ARCH trial). Probabilities of attaining the BMD target within 1 year of treatment were also determined. At both skeletal sites, in women with a baseline <i>T</i>score ≥ -2.7, there was >50% probability of achieving the BMD target with any 3-year regimen. The probability of achieving the target BMD in those with a baseline TH <i>T</i>score equal to -3.0 was 61% with romosozumab/denosumab, 38% with romosozumab/alendronate, and 9% with alendronate. In those with a baseline LS <i>T</i>score equal to -3.0, the probability of achieving a <i>T</i>-score > -2.5 was 93% with romosozumab/denosumab, 81% with romosozumab/alendronate, and 55% with alendronate. With 1 year of treatment, in patients with a baseline TH <i>T</i>-score equal to -2.7, the probability of reaching the target <i>T</i>score with romosozumab was 71% to 78% and 38% with alendronate. For patients with an initial LS <i>T</i>-score equal to -3.0, the probability of achieving the target <i>T</i>-score over 1 year was 85% to 86% with romosozumab and 25% for alendronate. Our findings suggest baseline BMD and the probability of achieving BMD <i>T</i>-score goals are factors to consider when selecting initial treatment for patients with osteoporosis. As baseline <i>T</i>-score falls below -2.7 (TH) and -3.0 (LS), alendronate has <50% likelihood of achieving a BMD goal above osteoporosis range, whereas these probabilities remain relatively high for regimens beginning with romosozumab. © 2021 The Authors. <i>JBMR Plus</i> published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research."],"journal":["JBMR plus"],"pagination":["e10546"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8567484"],"repository":["biostudies-literature"],"pubmed_title":["Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals."],"pmcid":["PMC8567484"],"pubmed_authors":["Bertoldo F","Lespessailles E","Cosman F","Ferrari S","Peris P","Libanati C","Hesse E","Yu Z","Wang Z","Deignan C","Cummings SR","Beck Jensen JE"],"additional_accession":[]},"is_claimable":false,"name":"Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals.","description":"Increases in bone mineral density (BMD) with osteoporosis treatment are associated with reduced fracture risk. Increasing BMD is therefore a goal of osteoporosis therapy. Here, we compare the probability of achieving a <i>T</i>-score of > -2.5 over 3 years at the total hip (TH) or lumbar spine (LS) in women with osteoporosis, ≥55 years of age, after the following treatment sequences: 1 year romosozumab followed by 2 years denosumab (FRAME and FRAME extension trials), 1 year romosozumab followed by 2 years alendronate, or alendronate-only for 3 years (ARCH trial). Probabilities of attaining the BMD target within 1 year of treatment were also determined. At both skeletal sites, in women with a baseline <i>T</i>score ≥ -2.7, there was >50% probability of achieving the BMD target with any 3-year regimen. The probability of achieving the target BMD in those with a baseline TH <i>T</i>score equal to -3.0 was 61% with romosozumab/denosumab, 38% with romosozumab/alendronate, and 9% with alendronate. In those with a baseline LS <i>T</i>score equal to -3.0, the probability of achieving a <i>T</i>-score > -2.5 was 93% with romosozumab/denosumab, 81% with romosozumab/alendronate, and 55% with alendronate. With 1 year of treatment, in patients with a baseline TH <i>T</i>-score equal to -2.7, the probability of reaching the target <i>T</i>score with romosozumab was 71% to 78% and 38% with alendronate. For patients with an initial LS <i>T</i>-score equal to -3.0, the probability of achieving the target <i>T</i>-score over 1 year was 85% to 86% with romosozumab and 25% for alendronate. Our findings suggest baseline BMD and the probability of achieving BMD <i>T</i>-score goals are factors to consider when selecting initial treatment for patients with osteoporosis. As baseline <i>T</i>-score falls below -2.7 (TH) and -3.0 (LS), alendronate has <50% likelihood of achieving a BMD goal above osteoporosis range, whereas these probabilities remain relatively high for regimens beginning with romosozumab. © 2021 The Authors. <i>JBMR Plus</i> published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2024-02-15T09:08:28.09Z","creation":"2022-02-11T12:41:21.294Z"},"accession":"S-EPMC8567484","cross_references":{"pubmed":["34761149"],"doi":["10.1002/jbm4.10546"]}}